Grindr Inc
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
GRND$13.47+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
During the Company’s last fiscal quarter, certain of the Company’s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of our securities as set forth in the table below:
| Type of Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Adoption/Termination Date · Rule 10b5-1(1) · Non-Rule 10b5-1(2) · Total Shares of Common Stock to be Sold(3) · Expiration Date | |||||
| Vandana Mehta-Krantz, Chief Financial Officer | Termination | 12/03/2024(4) | X | 100,000 | 11/12/2025 |
| Vandana Mehta-Krantz, Chief Financial Officer | Adoption | 12/10/2024 | X | 43,565 | 3/31/2026 |
| (1) | Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
| (2) | “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. |
| (3) | Represents the maximum number of shares that may be sold pursuant to the Rule 10b5-1 arrangement. The actual number of shares sold was dependent on the satisfaction of certain conditions as set forth in the written plan. |
| (4) | Represents the termination of a written plan originally adopted on August 13, 2024 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.